EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES: AN OPEN-LABEL, PHASE-III, EXTENSION STUDY

被引：4
|
作者：
Brogan, P. A. [1 ,2 ]
Hofer, M. [3 ]
Kuemmerle-Deschner, J. B. [4 ]
Lauwerys, B. [5 ,6 ]
Speziale, A. [7 ]
Leon, K. [8 ]
Wei, X. [9 ]
Laxer, R. [10 ]
机构：
[1] UCL Inst Child Hlth, Dept Infect Inflammat & Rheumatol, London, England
[2] Great Ormond St Hosp NHS Fdn Trust, London, England
[3] Hosp Univ Vaudois, Unite Romande Rhumatol Pediat, Lausanne, Switzerland
[4] Univ Hosp Tuebingen, Tubingen, Germany
[5] Clin Univ St Luc, Brussels, Belgium
[6] Catholic Univ Louvain, Brussels, Belgium
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut, Beijing, Peoples R China
[10] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.4865
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0503
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
    Brogan, Paul
    Hofer, Michael
    Kuemmerle-Deschner, Jasmin B.
    Lauwerys, Bernard
    Speziale, Antonio
    Leon, Karolynn
    Wei, Xiaoling
    Laxer, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients
    Yokota, S.
    Imagawa, T.
    Nishikomori, R.
    Takada, H.
    Abrams, K.
    Lheritier, K.
    Heike, T.
    Hara, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (06) : S19 - S26
  • [3] Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
    Kuemmerle-Deschner, Jasmin B.
    Hachulla, E.
    Cartwright, R.
    Hawkins, P. N.
    Tran, T. A.
    Bader-Meunier, B.
    Hoyer, J.
    Gattorno, M.
    Gul, A.
    Smith, J.
    Leslie, K. S.
    Jimenez, S.
    Morell-Dubois, S.
    Davis, N.
    Patel, N.
    Widmer, A.
    Preiss, R.
    Lachmann, H. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (12) : 2095 - 2102
  • [4] Canakinumab In Patients with Cryopyrin-Associated Periodic Syndromes
    Curran, Monique P.
    BIODRUGS, 2012, 26 (01) : 53 - 59
  • [5] Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results)
    Imagawa, T.
    Nishikomori, R.
    Takada, H.
    Takeshita, S.
    Patel, N.
    Kim, D.
    Lheritier, K.
    Heike, T.
    Hara, T.
    Yokota, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (02) : 302 - 309
  • [6] Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort
    Anton, J.
    Calvo, I.
    Fernandez-Martin, J.
    Gamir, M. L.
    Merino, R.
    Jimenez-Trevino, S.
    Sevilla, B.
    Cabades, F.
    Bou, R.
    Arostegui, J. I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (06) : S67 - S71
  • [7] Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study
    Krause, Karoline
    Mahamed, Aos
    Weller, Karsten
    Metz, Martin
    Zuberbier, Torsten
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (03) : 751 - 754
  • [8] Efficacy and safety of Canakinumab (ILARIS®) in Cryopyrin-Associated Periodic Syndrome (CAPS): Interim results of an onging phase III study
    Leslie, K. S.
    Kuemmerle-Deschner, J. B.
    Lachmann, H. J.
    Hachulla, E.
    Hoyer, J.
    Smith, J.
    Kone-Paut, I.
    Braun, I.
    Widmer, A.
    Patel, N.
    Preiss, R.
    Hawkins, P. N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S9 - S9
  • [9] Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
    Brogan, Paul
    Hofer, Michael
    Kuemmerle-Deschner, Jasmin B.
    Lauwerys, Bernard R.
    Speziale, Antonio
    Wei, Xiaoling
    Laxer, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 : 115 - 116
  • [10] Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
    Brogan, Paul
    Hofer, Michael
    Kuemmerle-Deschner, Jasmin B.
    Lauwerys, Bernard
    Speziale, Antonio
    Wei, Xiaoling
    Laxer, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345